Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
用户bdsY2U1qcXNY
25天前
70
10
已完结
1. 系统已在2026-02-03 12:28:36对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S2468-1253(25)00296-1
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125325002961
其他信息:
出版社: Elsevier BV
作者: Vipul Jairath; Silvio Danese; Geert R D’Haens; Brian G Feagan; Laurent Peyrin-Biroulet; Bruce E Sands; Ingrid Gaemers; Matt Westfall; Allyson Q Terry; Kevin J Roberts; Sara Barbat; Pamela Wedel; Jacqueline M Benson; Carlos Sattler
